These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 11061654)

  • 21. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level.
    Viard JP; Burgard M; Hubert JB; Aaron L; Rabian C; Pertuiset N; Lourenço M; Rothschild C; Rouzioux C
    AIDS; 2004 Jan; 18(1):45-9. PubMed ID: 15090828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
    Collazos J; Asensi V; Cartón JA
    AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.
    Grabar S; Le Moing V; Goujard C; Leport C; Kazatchkine MD; Costagliola D; Weiss L
    Ann Intern Med; 2000 Sep; 133(6):401-10. PubMed ID: 10975957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL).
    Floridia M; Bucciardini R; Fragola V; Galluzzo CM; Giannini G; Pirillo MF; Amici R; Andreotti M; Ricciardulli D; Tomino C; Vella S;
    HIV Med; 2004 Jan; 5(1):1-10. PubMed ID: 14731162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA.
    Cu-Uvin S; Caliendo AM; Reinert S; Chang A; Juliano-Remollino C; Flanigan TP; Mayer KH; Carpenter CC
    AIDS; 2000 Mar; 14(4):415-21. PubMed ID: 10770544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.
    Murphy EL; Collier AC; Kalish LA; Assmann SF; Para MF; Flanigan TP; Kumar PN; Mintz L; Wallach FR; Nemo GJ;
    Ann Intern Med; 2001 Jul; 135(1):17-26. PubMed ID: 11434728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy.
    Ghaffari G; Passalacqua DJ; Caicedo JL; Goodenow MM; Sleasman JW
    Pediatrics; 2004 Nov; 114(5):e604-11. PubMed ID: 15492356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.
    Deeks SG; Hecht FM; Swanson M; Elbeik T; Loftus R; Cohen PT; Grant RM
    AIDS; 1999 Apr; 13(6):F35-43. PubMed ID: 10397555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study.
    Carosi G; Castelli F; Suter F; Maggiolo F; Orani AM; Pan A; Andreoni M; Vigevani GM; Maserati R; Mazzotta F; Tinelli C;
    HIV Clin Trials; 2001; 2(5):399-407. PubMed ID: 11673814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.
    Thorsteinsson K; Ladelund S; Jensen-Fangel S; Johansen IS; Katzenstein TL; Pedersen G; Storgaard M; Obel N; Lebech AM
    BMC Infect Dis; 2012 Nov; 12():293. PubMed ID: 23140254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
    Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
    PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?
    Mocroft A; Gill MJ; Davidson W; Phillips AN
    J Acquir Immune Defic Syndr; 2000 Aug; 24(5):475-82. PubMed ID: 11035619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch.
    Tomasoni LR; Patroni A; Torti C; Paraninfo G; Gargiulo F; Quiros-Roldan E; Uccelli MC; Airò P; Tinelli C; Carosi G; Castelli F;
    HIV Clin Trials; 2003; 4(5):311-23. PubMed ID: 14583847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.
    Hulgan T; Shepherd BE; Raffanti SP; Fusco JS; Beckerman R; Barkanic G; Sterling TR
    J Infect Dis; 2007 Feb; 195(3):425-31. PubMed ID: 17205482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.